Last viewed:
ABMD
Prices are updated after-hours
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(0.0% 1y)
(0.0% 2d)
(0.0% 3d)
(0.0% 7d)
(758.37%
volume)
Earnings Calendar: 2023-02-02
Market Cap: $ 17,180,642,928
http://www.abiomed.com
Sec
Filling
|
Patents
| 1536 employees
(US) ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.
heart
brands
add to watch list
Paper trade
email alert is off
Press-releases
Global Cardiac Assist Devices Market Research Report 2023: Market to Reach $6.23 billion by 2028 - Growing Patient Pool and New Product Launches Driving New Opportunities
Published: 2023-11-22
(Crawled : 16:00)
- prnewswire.com
TFX
|
News
|
$206.23
-0.56%
140K
|
Health Technology
| -4.12%
| O: 0.9%
H: 0.43%
C: -0.13%
ABT
|
News
|
$106.76
1.42%
3.8M
|
Health Technology
| 4.9%
| O: 1.05%
H: 0.0%
C: 0.0%
report
cardiac
reach
research
global
growing
market
Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium
Published: 2023-10-23
(Crawled : 13:30)
- biospace.com/
JNJ
|
News
|
$147.895
1.48%
5.8M
|
Health Technology
| -4.84%
| O: 0.28%
H: 0.0%
C: 0.0%
symposium
Global Heart Failure Devices Market Analysis Report 2022-2023 & 2029: Vast Pipeline Products, Increase in Product Approvals, Availability of Alternative Products
Published: 2023-04-21
(Crawled : 10:00)
- prnewswire.com
TFX
|
News
|
$206.23
-0.56%
140K
|
Health Technology
| -22.39%
| O: 0.5%
H: 0.91%
C: 0.13%
MDT
|
$79.255
0.08%
2.6M
|
Health Technology
| -5.28%
| O: 0.89%
H: 4.63%
C: 1.78%
EW
|
News
|
$85.685
-0.89%
1.8M
|
Health Technology
| 1.78%
| O: 0.61%
H: 0.87%
C: 0.34%
BSX
|
$67.235
-0.27%
3.7M
|
Health Technology
| 28.13%
| O: 0.82%
H: 0.3%
C: -3.66%
ABT
|
News
|
$106.76
1.42%
3.8M
|
Health Technology
| -3.58%
| O: 0.48%
H: 1.12%
C: 0.7%
LIVN
|
$52.115
-1.22%
190K
|
Health Technology
| 4.51%
| O: 0.16%
H: 0.72%
C: 0.22%
CSII
|
$20.0
-0.05%
400K
|
Health Technology
| 0.15%
| O: -0.05%
H: 0.1%
C: 0.1%
ATRC
|
$23.2
-0.81%
260K
|
Health Technology
| -44.84%
| O: 0.76%
H: 0.57%
C: -0.59%
report
pipeline
global
heart
alternative
market
Johnson & Johnson Completes Acquisition of Abiomed
Published: 2022-12-22
(Crawled : 18:00)
- biospace.com/
JNJ
|
News
|
$147.895
1.48%
5.8M
|
Health Technology
| -18.42%
| O: -0.51%
H: 0.42%
C: 0.15%
acquisition
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
Published: 2022-12-21
(Crawled : 14:20)
- biospace.com/
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
| 0.06%
| O: -0.0%
H: 0.13%
C: 0.06%
fda
heart
trial
First Patients in the World Treated with Impella RP Flex with SmartAssist
Published: 2022-12-05
(Crawled : 14:00)
- biospace.com/
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
| 1.09%
| O: 0.08%
H: 0.36%
C: 0.27%
INVESTOR ALERT: The M&A Class Action Firm Continues Investigating the Merger - ABMD, AGFS, AKUS, AIMC
Published: 2022-11-17
(Crawled : 23:00)
- prnewswire.com
RRX
|
$159.895
2.53%
360K
|
Manufacturing
| 26.4%
| O: 1.91%
H: 1.25%
C: 0.89%
JNJ
|
News
|
$147.895
1.48%
5.8M
|
Health Technology
| -16.23%
| O: 1.12%
H: 0.0%
C: 0.0%
LLY
|
$727.48
-2.48%
2M
|
Health Technology
| 108.1%
| O: 0.49%
H: 0.58%
C: -0.24%
aigc
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of ABIOMED, Inc. - ABMD
Published: 2022-11-02
(Crawled : 03:00)
- prnewswire.com
JNJ
|
News
|
$147.895
1.48%
5.8M
|
Health Technology
| -16.6%
| O: -0.66%
H: 0.0%
C: 0.0%
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
| 0.49%
| O: -0.38%
H: 0.0%
C: 0.0%
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
Published: 2022-11-01
(Crawled : 12:00)
- biospace.com/
JNJ
|
News
|
$147.895
1.48%
5.8M
|
Health Technology
| -16.9%
| O: -0.36%
H: 0.0%
C: 0.0%
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
| 48.85%
| O: 48.12%
H: 0.0%
C: 0.0%
year
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
Published: 2022-10-31
(Crawled : 15:00)
- biospace.com/
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
| 47.65%
| O: -0.81%
H: 0.0%
C: 0.0%
fda
heart
approval
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001415889-22-013033
4
2022-12-28
2022-12-22
Sell
D
123370
0
0001415889-22-013031
4
2022-12-28
2022-12-22
Sell
D
3255
0